Canadian Evidence-based Guideline for the First-line Treatment of Chronic Lymphocytic Leukemia

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2018 Nov 23

PMID 30464698

Citations 7

Authors

C Owen

A S Gerrie

V Banerji

S Assouline

C Chen

K S Robinson

E Lye

G Fraser

Affiliations

Soon will be listed here.

Abstract

Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In Canada, no unified national guideline exists for the front-line treatment of cll; provincial guidelines vary and are largely based on funding. A group of clinical experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of cll. Consensus recommendations based on available evidence are presented for the first-line treatment of cll.

Citing Articles

An approach to anxiety during watch-and-wait for Chronic Lymphocytic Leukemia: Monitor and move on.

Cox-Kennett N Can Oncol Nurs J. 2024; 33(4):475-479.

PMID: 38919588 PMC: 11195816.

Cox-Kennett N Can Oncol Nurs J. 2024; 33(4):480-485.

PMID: 38919586 PMC: 11195818.

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.

Yang J, Yang L, Tordon B, Bucher O, Nugent Z, Landego I Curr Oncol. 2023; 30(7):6411-6431.

PMID: 37504332 PMC: 10378068. DOI: 10.3390/curroncol30070472.

Expert consensus on the management of chronic lymphocytic leukaemia in Asia.

Tse E, Kwong Y, Goh Y, Bee P, Ng S, Tan D Clin Exp Med. 2023; 23(6):2895-2907.

PMID: 36795237 PMC: 10543526. DOI: 10.1007/s10238-023-01007-2.

Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario.

Seung S, Hurry M, Hassan S, Elnoursi A, Scheider K, Wagner D Curr Oncol. 2021; 28(6):4832-4844.

PMID: 34898565 PMC: 8628804. DOI: 10.3390/curroncol28060408.

References

Jones J, Ruppert A, Zhao W, Lin T, Rai K, Peterson B . Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leuk Lymphoma. 2013; 54(12):2654-9. PMC: 3766417. DOI: 10.3109/10428194.2013.788179. View

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K . Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014; 123(21):3247-54. DOI: 10.1182/blood-2014-01-546150. View

Burger J, Tedeschi A, Barr P, Robak T, Owen C, Ghia P . Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 373(25):2425-37. PMC: 4722809. DOI: 10.1056/NEJMoa1509388. View

Byrd J, Peterson B, Morrison V, Park K, Jacobson R, Hoke E . Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2002; 101(1):6-14. DOI: 10.1182/blood-2002-04-1258. View

Magni M, Di Nicola M, Patti C, Scime R, Mule A, Rambaldi A . Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplant. 2014; 49(4):485-91. DOI: 10.1038/bmt.2013.214. View

Hallek M . Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015; 90(5):446-60. DOI: 10.1002/ajh.23979. View

Mauro F, Bandini G, Barosi G, Billio A, Brugiatelli M, Cuneo A . SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. Leuk Res. 2011; 36(4):459-66. DOI: 10.1016/j.leukres.2011.08.013. View

Farooqui M, Valdez J, Martyr S, Aue G, Saba N, Niemann C . Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015; 16(2):169-76. PMC: 4342187. DOI: 10.1016/S1470-2045(14)71182-9. View

Eichhorst B, Busch R, Stilgenbauer S, Stauch M, Bergmann M, Ritgen M . First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009; 114(16):3382-91. DOI: 10.1182/blood-2009-02-206185. View

10.

da Cunha-Bang C, Christiansen I, Niemann C . The CLL-IPI applied in a population-based cohort. Blood. 2016; 128(17):2181-2183. DOI: 10.1182/blood-2016-07-724740. View

11.

Fischer K, Cramer P, Busch R, Bottcher S, Bahlo J, Schubert J . Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012; 30(26):3209-16. DOI: 10.1200/JCO.2011.39.2688. View

12.

Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747):1164-74. DOI: 10.1016/S0140-6736(10)61381-5. View

13.

Kay N, Geyer S, Call T, Shanafelt T, Zent C, Jelinek D . Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2006; 109(2):405-11. PMC: 1785105. DOI: 10.1182/blood-2006-07-033274. View

14.

Fischer K, Bahlo J, Fink A, Goede V, Herling C, Cramer P . Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2015; 127(2):208-15. DOI: 10.1182/blood-2015-06-651125. View

15.

Pflug N, Bahlo J, Shanafelt T, Eichhorst B, Bergmann M, Elter T . Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014; 124(1):49-62. PMC: 4260976. DOI: 10.1182/blood-2014-02-556399. View

16.

Bosch F, Abrisqueta P, Villamor N, Terol M, Gonzalez-Barca E, Ferra C . Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009; 27(27):4578-84. DOI: 10.1200/JCO.2009.22.0442. View

17.

Rozman C, Montserrat E . Chronic lymphocytic leukemia. N Engl J Med. 1995; 333(16):1052-7. DOI: 10.1056/NEJM199510193331606. View

18.

Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R . Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998; 338(21):1506-14. DOI: 10.1056/NEJM199805213382104. View

19.

Del Poeta G, Del Principe M, Buccisano F, Maurillo L, Capelli G, Luciano F . Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer. 2007; 112(1):119-28. DOI: 10.1002/cncr.23144. View

20.

Shanafelt T, Ramsay A, Zent C, Leis J, Tun H, Call T . Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013; 121(20):4137-41. DOI: 10.1182/blood-2012-12-470005. View